<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01460966</url>
  </required_header>
  <id_info>
    <org_study_id>D110922004</org_study_id>
    <nct_id>NCT01460966</nct_id>
  </id_info>
  <brief_title>Assessment of Distal Protection Device in Patients at High Risk for Distal Embolism in Acute Coronary Syndrome (ACS)</brief_title>
  <acronym>VAMPIRE3</acronym>
  <official_title>Assessment of Distal Protection Device in Patients at High Risk for Distal Embolism in Acute Coronary Syndrome (ACS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yokohama City University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Teikyo University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yokohama City University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Attenuated plaque ≥ 5mm by intravascular ultrasound(IVUS) was reported to be high risk for
      distal embolism in Acute coronary syndrome(ACS). The purpose of this study is to assess the
      effect of thrombus aspiration catheter and distal protection device (filter wire; Filtrap™)
      in the aforementioned subgroup of patients at high risk for distal embolism.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">January 31, 2017</completion_date>
  <primary_completion_date type="Actual">December 23, 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of no-reflow/slow-flow phenomenon after percutaneous coronary intervention (PCI)</measure>
    <time_frame>a day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rise in CK-MB and troponin I or T the next morning after PCI (Peak of CK too in case of ST-segment elevation myocardial infarction )</measure>
    <time_frame>a day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinical events including mortality, major adverse cardiac events, and Hospitalization for heart failure</measure>
    <time_frame>10months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of Thrombolysis in Myocardial Infarction (TIMI) flow grade compared with baseline</measure>
    <time_frame>8-12months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TIMI flow grade</measure>
    <time_frame>8-12months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corrected TIMI frame count</measure>
    <time_frame>8-12months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial blush grade</measure>
    <time_frame>8-12months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of any revascularization</measure>
    <time_frame>8-12months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of stent thrombosis</measure>
    <time_frame>8-12months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plaque protrusion by IVUS inside the stent</measure>
    <time_frame>8-12months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Filtrap™+ Thrombus aspiration catheter</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Thrombus aspiration catheter</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Filtrap™ + Thrombus aspiration catheter</intervention_name>
    <description>Combination of distal protection device (Filtrap™ )and thrombus aspiration catheter</description>
    <arm_group_label>Filtrap™+ Thrombus aspiration catheter</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Thrombus aspiration catheter</intervention_name>
    <description>Thrombus aspiration catheter only</description>
    <arm_group_label>Thrombus aspiration catheter</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients who were diagnosed as ACS and meet the following criteria.

          -  Patients with acute myocardial infarction or unstable angina within 2 months from
             onset.

          -  Patients who have severe coronary stenosis which require PCI and in whom attenuated
             plaque ≥ 5mm (longitudinally) by IVUS before PCI is observed prior to balloon
             dilatation and stent deployment.

        Exclusion Criteria:

          -  Patients who need balloon expansion (including small diameter balloon) for IVUS
             catheter crossing.

          -  Patients who were resuscitated after dead on arrival

          -  Graft lesion or in-stent restenosis lesion

          -  Patients on dialysis or renal failure (Cr&gt;1.5mg/dl).

          -  Left main trunk lesion

          -  Target vessel size is &lt;2.5mm or &gt;5mm

          -  Ineligible for PCI

          -  Lactating and (possibly) pregnant woman or having possibility of pregnant

          -  Patients who are considered ineligible by the attending physician
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kiyoshi Hibi, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Yokohama City Universiy Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yokohama City University Medical Center</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>232-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2011</study_first_submitted>
  <study_first_submitted_qc>October 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2011</study_first_posted>
  <last_update_submitted>April 19, 2017</last_update_submitted>
  <last_update_submitted_qc>April 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yokohama City University Medical Center</investigator_affiliation>
    <investigator_full_name>Kiyoshi Hibi</investigator_full_name>
    <investigator_title>Yokohama City University Medical Center</investigator_title>
  </responsible_party>
  <keyword>Distal protection device</keyword>
  <keyword>Thrombus aspiration</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Coronary Disease</keyword>
  <keyword>Acute Coronary Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Embolism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

